Clinical Trial Detail

NCT ID NCT03008278
Title Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

gastroesophageal junction adenocarcinoma

stomach carcinoma

Therapies

Olaparib + Ramucirumab

Age Groups: senior adult

No variant requirements are available.